ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / BJDX / insiders
IVF (35) ICCM (33) CODX (29) AMIX (34) ⌘ Pro Terminal β†’

Bluejay Diagnostics Inc. (BJDX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$0.53 -4.74% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.52

Bluejay Diagnostics Inc. (BJDX) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $2.5M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BJDX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is BJDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Bluejay Diagnostics Inc. (NASDAQ: BJDX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.53 (-4.74% 1D, market cap $2.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BJDX ranks #524 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does BJDX compare to IVF and ICCM in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), BJDX carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, IVF (INVO Fertility Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.2M) and ICCM (IceCure Medical Ltd.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $3.0M). Among the 5-stock peer group, BJDX leads on earnings multiple (N/A) while BJDX leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BJDX?
β–Ό

Per BJDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001704287), Bluejay Diagnostics Inc. generated $19.5M in revenue (-3.0% YoY), -$6.8M in net income, and -$6.2M in free cash flow against $7.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.52 (-1.04%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (38/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510038
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D
Cash (8)Whales (5)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
$8 Bull$0 Base$0 Bear
πŸ“¬ FREE BJDX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for BJDX)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
πŸ” WHY BJDX SCORES 38/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–² #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime Γ— Technicals: 2% of 52W Range β€’ RSI-14 at 31.7 (OVERSOLD (<32))

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
46
Grade D$0.83-19.3% Next Q
Q2 (-2Q)
43
Grade D$0.67-13.4% Next Q
Q3 (-1Q)
41
Grade D$0.58-8.6% Next Q
Current
38
Grade D-$0.53-7.8% Hist 90D Ξ±
Trajectory: D (46) β†’ D- (38)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a BJDX Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While BJDX currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.81) and Max Pain ($0.56) forces dealer call-delta covering toward $8.34.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BJDXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œBJDX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 38%NO 62%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

BJDX Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BJDX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on BJDX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BJDX)

  • βœ“Walkthrough of BJDX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
BJDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -71.81%β–² RESISTANCE BREAKOUT
2026-11-03O $0.54H $0.56L $0.53C $0.53VOL 280.9K
RES: $0.43SUP: $0.44SMA50: $0.81SMA200: $1.82
$7.46$5.56$3.66$1.77$-0.13RES $0.43SUP $0.44$0.532026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BJDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ BJDX Butterfly Map β†’ + Track BJDX β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -3.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BJDX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for BJDX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BJDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BJDX)

Health Care Rank #524 of 1015 βš”οΈ IVF vs BJDX Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (BJDX vs. IVF, ICCM, CODX, AMIX)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Bluejay Diagnostics Inc. (BJDX) ranks #524 by composite RQD confidence (38/100, grade D-) and #984 by equity capitalization ($2.5M). Within this direct 5-issuer industry benchmark cohort, BJDX leads on earnings valuation at N/A trailing P/E, while BJDX leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. BJDX currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BJDX ACTIVE
Bluejay Diagnostics Inc.
D- 38/100 β€” β€” -35.0% -4.74% $2.5M Benchmark Subject
IVF
INVO Fertility Inc.
D- 35/100 β€” 96.0% -35.0% -4.19% $2.2M /ivf-vs-bjdx β†’
ICCM
IceCure Medical Ltd.
E 33/100 β€” 36.3% -35.0% -3.14% $3.0M /iccm-vs-bjdx β†’
CODX
Co-Diagnostics Inc.
E 29/100 β€” 64.3% -35.0% -3.65% $3.2M /codx-vs-bjdx β†’
AMIX
Autonomix Medical Inc.
E 34/100 β€” β€” -35.0% -7.18% $3.5M /amix-vs-bjdx β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001704287 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bluejay Diagnostics Inc. (BJDX) reported GAAP revenue of $19.5M (-3.0% vs. FY2024 revenue of $20.1M , and -32.6% cumulative change since FY2023) , GAAP net income of -$6.8M, operating cash flow of -$6.1M, and free cash flow of -$6.2M (+23.4% YoY). On the balance sheet, BJDX closed FY2025 with $7.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $19.5M -$6.8M -$6.1M -$6.2M $7.1M β€”
FY2024 (FY) 2024-12-31 $20.1M -$7.7M -$7.8M -$8.1M $6.7M β€”
FY2023 (FY) 2023-12-31 $28.9M -$10.0M -$8.3M -$8.3M β€” β€”

3. BJDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BJDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Bluejay Diagnostics Inc. (NASDAQ: BJDX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.53 (-4.74% 1D, market cap $2.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BJDX ranks #524 in composite RQD confidence.

How does BJDX compare to IVF and ICCM in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), BJDX carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, IVF (INVO Fertility Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.2M) and ICCM (IceCure Medical Ltd.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $3.0M). Among the 5-stock peer group, BJDX leads on earnings multiple (N/A) while BJDX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BJDX?

Per BJDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001704287), Bluejay Diagnostics Inc. generated $19.5M in revenue (-3.0% YoY), -$6.8M in net income, and -$6.2M in free cash flow against $7.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BJDX trading relative to its 50-day, 200-day, and 52-week technical levels?

BJDX last traded at $0.53 (-4.74% on volume of 197,726 shares), positioning the stock -34.57% below its 50-day simple moving average ($0.81) and -70.88% below its 200-day simple moving average ($1.82). Across its 52-week range of $0.46 to $7.94, BJDX sits at the 0.9% percentile with a 14-day RSI of 31.7 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($1.00 to $0.60).

Direct Sub-Reports: BJDX RQD Cockpit BJDX 12M Forecast BJDX Earnings & Move BJDX Dividends & DRIP BJDX Insiders & 13F BJDX Whale Options BJDX Profit Sankey BJDX News & Why
ROARABLE RATING BRIEF β€’ RQD 38/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

BJDX β€” Bluejay Diagnostics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Bluejay Diagnostics Inc. (BJDX) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.53 (-4.74% 1D, market capitalization $2.5M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Bluejay Diagnostics Inc. (BJDX) is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry. It is a Health Care issuer operating in Medical/Dental Instruments. Reported revenue in each of the three SEC financial periods is β€”, so the source does not show a commercial revenue stream in the periods provided.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Bluejay Diagnostics Inc. (BJDX) reported $19.5M in annual revenue (up from $20.1M in FY2024, -3.0% YoY) and -$6.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($28.9M revenue, -$10.0M net income) through FY2025, BJDX scaled operating cash flow to -$6.1M and free cash flow to -$6.2M, backed by $7.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.46 – $7.94 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

β€” for upstream or downstream dependencies, sector correlation coefficients, or second-order bottlenecks.

  • Key Question #1: Can BJDX sustain or expand its β€” operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $19.5M and free cash flow of -$6.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BJDX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BJDX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Bluejay Diagnostics Inc. (BJDX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to BJDX Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BJDX Bull vs. Bear Conversation Board β€” What's Your Call at $0.53?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BJDX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BJDX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER β€’ Growth & Tech Investor πŸ‚ BULLISH 🎯 Target: $0.68 (+21.4%)
πŸ“Œ Pinned Debate

Balance sheet forensics are middling rather than distressed, with cash rising to $5.2M in FY 2025 and an Altman Z-Score of 2.5.

Balance sheet forensics are middling rather than distressed, with cash rising to $5.2M in FY 2025 and an Altman Z-Score of 2.5.. When you look under the hood at BJDX, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $7.94. My 12M target is $0.68.

SectorRotator πŸ‚ BULL

@FadeTheHype Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FA FadeTheHype RQD DEBATE OPENER β€’ Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $0.45 (-19.6%)
Spot @ $0.56

ROIC of -35% and zero FCF yield show the business is not currently converting capital into returns, with zero reported revenue across t

Here is the bear case nobody on the bull side wants to address on BJDX: ROIC of -35% and zero FCF yield show the business is not currently converting capital into returns, with zero reported revenue across three periods.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

LIVE TAPE